Is Zymeworks Inc. (ZYME) a Buy, Sell, or Hold?
Zymeworks Inc.
NYSE:ZYME
$14.09 USD
-$0.33 (-2.29%)
- Volume
- 333.17K
- Average Volume
- 576.59K
- Market Capitalization
- $970.48M
- P/E Ratio
- -9.44
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $17.70
- Year Low
- $7.97
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Industry, Sector & symbol
| Stock Exchange | New York Stock Exchange |
| CEO | Mr. Kenneth H. Galbraith C.A. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ZYME |
| CUSIP | 98985W102 |
| CIK | 0001403752 |
| Web | https://www.zymeworks.com |
| Phone | 16046781388 |
| Currency | USD |
| Employees | 294 |
| Country | CA |
Liquidity
| Debt-to-Equity Ratio | 89.32 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | $76.01M |
| Price / Sales | 15.60 |
| Cash Flow | -0.77 |
| Price / Cash Flow | -16.55 |
| Price / Book | 2.92 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $28.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | 17.42% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.72 |
| Trailing P/E Ratio | -9.44 |
| PEG Ratio | -7.17 |
| P/E Growth | -7.17 |
| Net Income | $-118.67M |
| Net Margin | -182.75% |
| Pretax Margin | -189.75% |
| Return on Equity | -27.13% |
| Return on Assets | -23.33% |
Financials Score
| AltmanZ Score | -203.98 |
| Piotroski Score | 2.00 |
| Working Capital | -83.57B |
| Total Assets | 487.15M |
| Ebit | -119.85M |
| Market Cap | 970.48M |
| Total Liabilities | 120.17M |
Poll Results
About Zymeworks Inc. (NYSE:ZYME) Stock
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Jan ... ssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Announces Participation in Upcoming Investor Conferences
2024-11-21 06:05:00
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
2024-11-21 06:00:00
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC.
2024-11-05 06:00:00
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
2024-11-04 04:28:41
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
2024-10-31 22:05:09
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by.
Frequently Asked Questions
-
What is the current Zymeworks Inc. (ZYME) stock price?
-
Zymeworks Inc.(NYSE:ZYME) stock price is $14.09 in the last trading session. During the trading session, ZYME stock reached the peak price of $17.7 while $7.97 was the lowest point it dropped to. The percentage change in ZYME stock occurred in the recent session was --2.29% while the dollar amount for the price change in ZYME stock was -$-0.33.
-
ZYME's industry and sector of operation?
-
The NYSE listed ZYME is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ZYME?
-
Mr. Kenneth H. Galbraith C.A. | Chairman of the Board, Chief Executive Officer & President
Ms. Shrinal Inamdar | Director of Investor Relations
Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development
Dr. Jeffrey Smith M.D. | Executive Vice President & Chief Medical Officer
Mr. John Fann Ph.D. | Senior Vice President of Process Sciences -
How many employees does ZYME have?
-
Number of ZYME employees currently stands at 294. ZYME operates from 114 East 4th Avenue, Vancouver, BC V5T 1G4, CA.
-
Link for ZYME official website?
-
Official Website of ZYME is: https://www.zymeworks.com
-
How do I contact ZYME?
-
ZYME could be contacted at phone #16046781388 and can also be accessed through its website. ZYME operates from 114 East 4th Avenue, Vancouver, BC V5T 1G4, CA.
-
How many shares of ZYME are traded daily?
-
The average number of ZYME shares traded daily for last 3 months was 576.59K.
-
What is the market cap of ZYME currently?
-
The market value of ZYME currently stands at $970.48M with its latest stock price at $14.09